Advertisement

Role and Therapeutic Implications of MDSCs in Sarcomas

  • Brittany Lala
  • Anusha Kalbasi
  • Arun S. SinghEmail author
Chapter

Abstract

Understanding the interplay of the positive and negative regulators of the immune system in sarcomagenesis will be crucial to identifying approaches to use immunotherapies for this rare and heterogeneous group of diseases. In this chapter, we explore the known role of myeloid-derived suppressor cells (MDSCs) in creating an immunosuppressive state in the tumor microenvironment. We highlight current issues with properly defining this heterogeneous continuum of cells with apparent context dependent phenotypic plasticity. Some of the known direct and indirect effects of MDSCs on immune effector cells are explored and several strategies aimed at inhibiting this immunosuppressive cellular compartment in model systems are examined. Further research is required to better characterize and understand the function of MDSCs and to study them in the human condition.

Keywords

Sarcoma Microenvironment MDSC Immunotherapy Immune evasion Macrophage 

References

  1. 1.
    Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. 2010;40:2969–75.CrossRefGoogle Scholar
  2. 2.
    Ugel S, De Sanctis F, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest. 2015;125:3365–76.CrossRefGoogle Scholar
  3. 3.
    Wesolowski R, Markowitz J, Carson WE. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer. 2013;1:10.CrossRefGoogle Scholar
  4. 4.
    Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–74.CrossRefGoogle Scholar
  5. 5.
    Solito S, et al. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci. 2014;1319:47–65.CrossRefGoogle Scholar
  6. 6.
    Highfill SL, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014;6:237ra267.CrossRefGoogle Scholar
  7. 7.
    Llitjos JF, et al. Sepsis-induced expansion of granulocytic myeloid-derived suppressor cells promotes tumour growth through Toll-like receptor 4. J Pathol. 2016;239:473–83.CrossRefGoogle Scholar
  8. 8.
    Adah D, et al. Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics. Pharmacol Res. 2016;110:25–34.CrossRefGoogle Scholar
  9. 9.
    Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv Cancer Res. 2015;128:95–139.CrossRefGoogle Scholar
  10. 10.
    Wang Z, Liu Y, Zhang Y, Shang Y, Gao Q. MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer. Oncotarget. 2016;7:4760–9.PubMedGoogle Scholar
  11. 11.
    Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016;16:447–62.CrossRefGoogle Scholar
  12. 12.
    Duncan BB, et al. A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy. J Immunother. 2013;36:400–11.CrossRefGoogle Scholar
  13. 13.
    Zhang H, et al. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood. 2013;122:1105–13.CrossRefGoogle Scholar
  14. 14.
    Zoso A, et al. Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. Eur J Immunol. 2014;44:3307–19.CrossRefGoogle Scholar
  15. 15.
    Vanderstraeten A, Luyten C, Verbist G, Tuyaerts S, Amant F. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother. 2014;63:545–57.CrossRefGoogle Scholar
  16. 16.
    Tazzari M, et al. Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. Br J Cancer. 2014;111:1350–62.CrossRefGoogle Scholar
  17. 17.
    Finkelstein SE, et al. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys. 2012;82:924–32.CrossRefGoogle Scholar
  18. 18.
    Hao Z, Sadek I. Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther. 2016;9:5495–505.CrossRefGoogle Scholar
  19. 19.
    Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004;172:989–99.CrossRefGoogle Scholar
  20. 20.
    Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001;61:4756–60.PubMedGoogle Scholar
  21. 21.
    Nagaraj S, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13:828–35.CrossRefGoogle Scholar
  22. 22.
    Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol. 2005;174:636–45.CrossRefGoogle Scholar
  23. 23.
    Motoshima T, et al. Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells. Oncol Rep. 2015;33:2947–53.CrossRefGoogle Scholar
  24. 24.
    Huang B, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66:1123–31.CrossRefGoogle Scholar
  25. 25.
    Yang R, et al. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res. 2006;66:6807–15.CrossRefGoogle Scholar
  26. 26.
    Movahedi K, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111:4233–44.CrossRefGoogle Scholar
  27. 27.
    Long AH, et al. Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol Res. 2016;4:869–80.CrossRefGoogle Scholar
  28. 28.
    Tsukamoto H, Nishikata R, Senju S, Nishimura Y. Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression. Cancer Immunol Res. 2013;1:64–76.CrossRefGoogle Scholar
  29. 29.
    Cheng P, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008;205:2235–49.CrossRefGoogle Scholar
  30. 30.
    Cohen PA, et al. Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. Immunol Investig. 2012;41:680–710.CrossRefGoogle Scholar
  31. 31.
    Geiger R, et al. L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 2016;167:829.e813–42.e813.CrossRefGoogle Scholar
  32. 32.
    Balachandran VP, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17:1094–100.CrossRefGoogle Scholar
  33. 33.
    Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707–23.CrossRefGoogle Scholar
  34. 34.
    Germano G, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23:249–62.CrossRefGoogle Scholar
  35. 35.
    Germano G, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010;70:2235–44.CrossRefGoogle Scholar
  36. 36.
    Rao A, et al. Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. Cancer Res. 2012;72:3196–206.CrossRefGoogle Scholar
  37. 37.
    Qu Y, et al. Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment. J Immunol. 2010;185:2895–902.CrossRefGoogle Scholar
  38. 38.
    Garton AJ, et al. Anti-KIT monoclonal antibody treatment enhances the antitumor activity of immune checkpoint inhibitors by reversing tumor-induced immunosuppression. Mol Cancer Ther. 2017;16:671–80.CrossRefGoogle Scholar
  39. 39.
    D’Angelo SP, et al. Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: a phase Ib study of dasatinib plus ipilimumab. Clin Cancer Res. 2017;23:2972–80.CrossRefGoogle Scholar
  40. 40.
    Fernandez A, et al. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. J Immunol. 2011;186:264–74.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Hematology and OncologyUniversity of California, Los AngelesSanta MonicaUSA
  2. 2.Department of Radiation OncologyUniversity of California, Los AngelesSanta MonicaUSA

Personalised recommendations